You just read:

High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection

News provided by

Bristol-Myers Squibb

23 Apr, 2013, 11:35 BST